Galventa, founded in 2018 and based in St. Gallen, develops nutraceuticals using clinically tested galenic platform technologies aimed at synchronising circadian rhythms. Its lead product, B・SYNC ON, is described as a world-first delayed-release wake-up supplement containing caffeine, vitamin B5 and B12, and zinc B to reduce tiredness and boost mental performance. The formulation is intended to help people wake up naturally after a full night’s sleep with sharper focus and a more positive mood. Galventa is part of the Founders Factory accelerator program and has conducted initial market tests ahead of a wider commercial launch. The company will use the €696K seed funding to expand its team, broaden its product portfolio, and scale up production. It plans to launch B・SYNC ON into European markets including Switzerland, Germany and the UK.

Total raised

$1M

Funding rounds

1

Latest round

Seed

Latest activity

Oct 2021